Secondary cancers after bone marrow transplantation

Michael Lishner; Ruth Lang; Robert P. Witherspoon; Lloyd D. Fisher; Keith M. Sullivan; Rainer Storb; E. Donnall Thomas

doi:10.1056/NEJM199003223221216

Secondary cancers after bone marrow transplantation

Michael Lishner, Ruth Lang, Robert P. Witherspoon, Lloyd D. Fisher, Keith M. Sullivan, Rainer Storb, E. Donnall Thomas

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Abstract

To the Editor: Witherspoon et al. (Sept. 21 issue)¹ analyzed the incidence of secondary cancers after bone marrow transplantation. Although they discuss the role of immunosuppression in the pathogenesis of secondary cancers, they provide no information about the relative risk in patients who underwent allogeneic bone marrow transplantation as compared with that in patients who underwent autologous or syngeneic transplantation. Since immunologic disorders after allogeneic bone marrow transplantation, including acute and chronic graft-versus-host disease, are often severe, and immunosuppressive treatment is frequently required, we would expect the incidence of secondary malignant tumors to be higher in recipients of allogeneic bone.

Original language	English
Pages (from-to)	853
Number of pages	1
Journal	New England Journal of Medicine
Volume	322
Issue number	12
DOIs	https://doi.org/10.1056/NEJM199003223221216
State	Published - 22 Mar 1990
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJM199003223221216

Cite this

@article{bac91f74b5f84beaa0a1626c73e1a2b1,

title = "Secondary cancers after bone marrow transplantation",

abstract = "To the Editor: Witherspoon et al. (Sept. 21 issue)1 analyzed the incidence of secondary cancers after bone marrow transplantation. Although they discuss the role of immunosuppression in the pathogenesis of secondary cancers, they provide no information about the relative risk in patients who underwent allogeneic bone marrow transplantation as compared with that in patients who underwent autologous or syngeneic transplantation. Since immunologic disorders after allogeneic bone marrow transplantation, including acute and chronic graft-versus-host disease, are often severe, and immunosuppressive treatment is frequently required, we would expect the incidence of secondary malignant tumors to be higher in recipients of allogeneic bone.",

author = "Michael Lishner and Ruth Lang and Witherspoon, {Robert P.} and Fisher, {Lloyd D.} and Sullivan, {Keith M.} and Rainer Storb and Thomas, {E. Donnall}",

year = "1990",

month = mar,

day = "22",

doi = "10.1056/NEJM199003223221216",

language = "אנגלית",

volume = "322",

pages = "853",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "12",

}

TY - JOUR

T1 - Secondary cancers after bone marrow transplantation

AU - Lishner, Michael

AU - Lang, Ruth

AU - Witherspoon, Robert P.

AU - Fisher, Lloyd D.

AU - Sullivan, Keith M.

AU - Storb, Rainer

AU - Thomas, E. Donnall

PY - 1990/3/22

Y1 - 1990/3/22

N2 - To the Editor: Witherspoon et al. (Sept. 21 issue)1 analyzed the incidence of secondary cancers after bone marrow transplantation. Although they discuss the role of immunosuppression in the pathogenesis of secondary cancers, they provide no information about the relative risk in patients who underwent allogeneic bone marrow transplantation as compared with that in patients who underwent autologous or syngeneic transplantation. Since immunologic disorders after allogeneic bone marrow transplantation, including acute and chronic graft-versus-host disease, are often severe, and immunosuppressive treatment is frequently required, we would expect the incidence of secondary malignant tumors to be higher in recipients of allogeneic bone.

AB - To the Editor: Witherspoon et al. (Sept. 21 issue)1 analyzed the incidence of secondary cancers after bone marrow transplantation. Although they discuss the role of immunosuppression in the pathogenesis of secondary cancers, they provide no information about the relative risk in patients who underwent allogeneic bone marrow transplantation as compared with that in patients who underwent autologous or syngeneic transplantation. Since immunologic disorders after allogeneic bone marrow transplantation, including acute and chronic graft-versus-host disease, are often severe, and immunosuppressive treatment is frequently required, we would expect the incidence of secondary malignant tumors to be higher in recipients of allogeneic bone.

UR - http://www.scopus.com/inward/record.url?scp=0025712643&partnerID=8YFLogxK

U2 - 10.1056/NEJM199003223221216

DO - 10.1056/NEJM199003223221216

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 2308621

AN - SCOPUS:0025712643

SN - 0028-4793

VL - 322

SP - 853

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 12

ER -

Secondary cancers after bone marrow transplantation

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this